Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185783 · ClinicalTrials.gov registry record
Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis
A clinical trial of Sepsis and Relative Adrenal Insufficiency, sponsored by Stanford University.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT00185783: Completed study of Sepsis and Relative Adrenal Insufficiency, sponsored by Stanford University.
NCT00185783 is a study of Sepsis and Relative Adrenal Insufficiency that has completed, run by Stanford University. The registered enrollment target is 10 participants, below the 6,565-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00185783, a study of Sepsis and Relative Adrenal Insufficiency, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study is to (1) examine the changes in gene expression in patients who suffer from severe sepsis and whose shock (inadequate oxygen delivery to vital organs) state does not respond to fluid and vasopressor administration, (2) to show that our sampling method of isolating RNA provides reliable and consistent data, (3) provide a basis for future gene expression studies in critically ill patients
Conditions Studied
Interventions
- DRUG Hydrocortisone Administration (Standard of Care Therapy)
Study Locations (1)
California
- Stanford University Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-11 |
What the finished NCT00185783 record still lists
NCT00185783 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 6,565-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Hydrocortisone Administration (Standard of Care Therapy) is the first listed.
NCT00185783 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00185783 about?
NCT00185783 is a clinical study titled "Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis". The purpose of this pilot study is to (1) examine the changes in gene expression in patients who suffer from severe sepsis and whose shock (inadequate oxygen delivery to vital organs) state does not respond to fluid and vasopressor administration, (2) to show that our sampling method of isolating RN...
What is the current status of trial NCT00185783?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2005-03. Estimated completion is 2006-11.
What conditions does trial NCT00185783 study?
This clinical trial studies the following conditions: Sepsis, Relative Adrenal Insufficiency.
What interventions are being tested in trial NCT00185783?
The interventions under investigation include: Hydrocortisone Administration (Standard of Care Therapy) (DRUG).
Who is sponsoring clinical trial NCT00185783?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00185783 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00185783's enrollment target sits among peer trials
10 85th of 90 higher than 5 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia